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Abstract
The genital human papillomaviruses (HPVs) are a taxonomic group including HPV types that preferentially cause genital and laryngeal
warts (“low-risk types”), such as HPV-6 and HPV-11, or cancer of the cervix and its precursor lesions (“high-risk types”), such as HPV-16.
The transforming processes induced by these viruses depend on the proteins E5, E6, and E7. Among these oncoproteins, the E6 protein
stands out because it supports a particularly large number of functions and interactions with cellular proteins, some of which are specific
for the carcinogenic HPVs, while others are shared among low- and high-risk HPVs. Here we report yeast two-hybrid screens with HPV-6
and -11 E6 proteins that identified TRIP-Br1 as a novel cellular target. TRIP-Br1 was recently detected by two research groups, which
described two separate functions, namely that of a transcriptional integrator of the E2F1/DP1/RB cell-cycle regulatory pathway (and then
named TRIP-Br1), and that of an antagonist of the cyclin-dependent kinase suppression of p16INK4a (and then named p34SEI-1). We
observed that TRIP-Br1 interacts with low- and high-risk HPV E6 proteins in yeast, in vitro and in mammalian cell cultures. Transcription
activation of a complex consisting of E2F1, DP1, and TRIP-Br1 was efficiently stimulated by both E6 proteins. TRIP-Br1 has an LLG E6
interaction motif, which contributed to the binding of E6 proteins. Apparently, E6 does not promote degradation of TRIP-Br1. Our
observations imply that the cell-cycle promoting transcription factor E2F1/DP1 is dually targeted by HPV oncoproteins, namely (i) by
interference of the E7 protein with repression by RB, and (ii) by the transcriptional cofactor function of the E6 protein. Our data reveal the
natural context of the transcription activator function of E6, which has been predicted without knowledge of the E2F1/DP1/TRIP-Br/E6
complex by studying chimeric constructs, and add a function to the limited number of transforming properties shared by low- and
high-risk HPVs.
© 2003 Elsevier Inc. All rights reserved.
Introduction
Among the three transforming genes of papillomaviruses
(Howley, 1996; IARC, 1995; zur Hausen, 1996), E6 has
attracted much interest due to the surprising diversity of the
functions of its product. The E6 oncoprotein has—in the
case of human papillomavirus 16 (HPV-16)—a size of 151
amino acids, and the positional conservation of eight cystein
residues and the protein’s ability to bind zinc ions suggest a
structure with two zinc fingers, with their large size of 29
amino acids unique among all known zinc finger proteins
(Ullman et al., 1996). For several years, there was only a
single paradigm for the function of the E6 protein, namely
binding and degrading, together with the ubiquitin ligase
E6AP, the transcription factor, and cell-cycle regulator p53
(Scheffner et al., 1990, 1993; Werness et al., 1990), an
obviously useful function of a virus with the strategy to
overcome cell-cycle repression and apoptosis. However,
more recently a surprising number of additional functions
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could be attributed to E6 proteins. Interactions of E6 pro-
teins with hDLG and paxillin may influence signaling from
the extracellular matrix to the nucleus and the cell shape
(Das et al., 2000; Kiyono et al., 1997; Lee et al., 1997;
Vande Poll et al., 1998), with E6BP calcium metabolism
(Chen et al., 1998), with IRF-3 the immuneresponse against
papillomavirus lesions (Ronco et al., 1998), with CBP tran-
scriptional regulation (Patel et al., 1999; Zimmermann et al.,
1999, 2000), and with a transcription factor regulating the
telomerase gene expression, the immortalization process
(Gewin and Galloway; 2001). These and other functions of
E6 proteins and their presence or absence in high-risk or
low-risk HPV types or the bovine papillomavirus-1 have
been reviewed (Degenhardt and Silverstein, 2001a,b; Kuhne
and Banks, 1998; Mantovani and Banks, 2001; Rapp and
Chen, 1998). Similarly, more than a dozen interactions with
cellular proteins have been reported for the second HPV
oncoprotein, E7 (reviewed in Munger et al., 2001).
Cancer of the cervix, caused by chronic infection of the
transformation zone of the cervix with the “high-risk” HPV
types HPV-16, HPV-18, and their relatives, is a more im-
portant public health problem than genital and laryngeal
warts, which are caused by HPV-6, HPV-11, and related
types (Chan et al., 1995). Many of the interactions between
the E6 and E7 oncoproteins and cellular targets are specific
for oncoproteins of the high-risk HPV types, while a subset
of these proteins also interacts with low-risk HPVs. Re-
cently, a cellular protein was observed for the first time that
can specifically bind the low-risk HPV-6 E6 but not several
other E6 proteins including those of high-risk types (De-
genhardt and Silverstein, 2001a). As one compares the con-
spicuous neoplasia caused by HPV-6 or HPV-11 with the
often barely detectable precursors of cervical malignant
lesions, cervical intraepithelial neoplasia (CIN), one has to
conclude that the oncoproteins of low-risk viruses must
have substantial molecular functions.
Against this background, we initiated this research in the
hope that screening for cellular proteins that interact with
the E6 oncoproteins of low-risk viruses would identify
novel targets that may be important during the etiology of
warts as opposed to CIN-like precursor lesions. In this
screen we found several interesting cellular candidates for
being HPV-6 and HPV-11 E6 targets, and in this article, we
describe the detection and functional analysis of one of
them, TRIP-Br1. While our data show how HPV E6 protein
chose yet another target among cell-cycle regulators, our
original goal, to find a target specific for wart viruses, was
not achieved, since TRIP-Br1 was similarly targeted by
HPV-16 E6. TRIP-Br1 has been independently described by
two different research groups (Hsu et al., 2001; Sugimoto et
al., 1999), which followed different experimental strategies
and consequently observed two different molecular proper-
ties of this protein. Sugimoto and colleagues (1999) de-
tected it in a yeast two-hybrid screen with INK4A as a bait
and termed it p34SEI-1 (SEI, selected with INK4). They
could show that it forms a quatemary complex with CDK4,
cyclin D, and INK4. In this complex, the p34SEI annihilates
the kinase inhibitory function of INK4, without displacing it
from CDK4. As a consequence, CDK4 can still phosphor-
ylate the retinoblastoma tumor suppressor (RB) protein,
relieving its transcriptional repression function on E2F1/
DP1, which is an important transcription factor at the G1/S
checkpoint of the cell cycle (reviewed in Trimarchi and
Lees, 2002). Hsu and colleagues (2001) found the same
protein in a screen originally aiming at proteins interacting
with the PHD-bromodomain of the transcriptional cofactor
KRIP-1 and termed it TRIP-Br1 (transcriptional regulator
interacting with the PHD-bromodomain, “1” indicating that
it was one member in a family of two related genes).
Subsequently, it became clear that TRIP-Br1 makes physi-
cal contact with the DP1 subunit of the E2F1/DP1 hetero-
mer, where it acts as a transcriptional coactivator. In sum-
mary, TRIP-Br1 stimulates transcription of cell-cycle
promoting and E2F1/DP1 regulated genes by two mecha-
nisms, release of repression of E2F1 by RB and as a tran-
scriptional coactivator of E2F1/DP1.
In this article, we report that HPV E6 oncoproteins bind
to and further increase the transcription stimulatory function
of TRIP-Br1. Our findings add another facet of knowledge
about the alterations of the E2F1/DP1/RB cell-cycle regu-
latory pathway by both papillomavirus oncoproteins, report
one of the few cellular proteins targeted both by high- and
low-risk HPVs, and point to the natural context of a previ-
ously predicted transcription factor function of E6 (De-
saintes et al., 1992; Lamberti et al., 1990; Ned et al., 1997).
Results
A yeast two-hybrid screen identifies the TRIP-Br1 cell-
cycle regulator as a target of the HPV-6 E6 protein
We cloned the HPV-16 E6 protein into the bait vector,
pAS2-1 (Clontech), and selected His/LacZ positive
clones of a human keratinocyte cDNA library with 5  106
independent inserts in pGAD10 (Clontech) vector. Among
100 arbitrarily chosen clones, nine encoded the E6AP ubiq-
uitin ligase, one of the best characterized HPV-16 E6 inter-
acting proteins (Scheffner et al., 1990, 1993; Werness et al.,
1990). Most of the remaining clones encoded frequently
encountered unspecifically binding proteins (e.g., heat
shock proteins). We transformed E6AP containing pGAD10
vectors into yeast expressing HPV-6 E6 protein from
pAS2-1 constructs and confirmed that they also led to a
His and LacZ phenotype, although the blue color in the
X-Gal test did not develop as strongly as with HPV-16 E6
clones. This was expected as the E6 proteins of low-risk
HPV-type E6 proteins are known to have less affinity to
E6AP than those of high-risk HPV types (Huibregtse et al.,
1993).
In a similar experiment with the HPV-6 E6 protein as
bait, we obtained only nine clones that were both His and
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scored positive in the X-gal test. None of these clones
contained an insert that had previously been reported as an
E6 target. Six of these clones unspecifically encoded bind-
ing cellular proteins, while three clones represented three
different genes that did not fall into this category. One of
these clones represented a cDNA with a length of 1.2 kb
containing a 711-bp open reading frame, whose sequence
was 100% identical to a gene in the data base that had been
previously characterized by two different groups and pub-
lished under the names p34SEI-1 (Sugimoto et al., 1999)
and TRIP-Br1 (Hsu et al., 2001) (GenBank Accession Nos.
NM013376 and AF366402). This clone was designated
pGAD10-TRIP-Br1. By using HPV-11 E6 as bait, we con-
firmed that this new interaction partner leads to similar
positively reacting clones as HPV-6 E6. This article deals
with the analysis of this new interaction, while the remain-
ing two proteins are still under investigation.
Low-risk and high-risk HPV E6 proteins interact with the
TRIP-Br1 protein
We had begun this project in the hope of detecting
cellular proteins that had functions preferentially in the
context of HPV types that generate genital warts, as op-
posed to cervical cancer precursors. To investigate this
possibility, we transformed pGAD10-TRIP-Br1 into Y190
cells containing pAS2-1 HPV-16 E6 vectors. Contrary to
our hopes, these experiments showed that Y190/pGAD10-
TRIP-Br1 cells grew equally well and gave color reactions
of similar intensity in X-Gal test in the presence of HPV-6,
HPV-11, or HPV-16 E6 protein. We conclude that in yeast
all three oncoproteins react similarly with TRIP-Br1.
Binding of TRIP-Br1 and HPV E6 proteins in vitro
To examine whether HPV E6 and TRIP-Br1 proteins
interact in vitro, we prepared GST fusion proteins of the
full-length HPV-16 and HPV-11 E6 protein, both being
efficiently expressed at similar levels in Escherichia coli
BL21, as shown in Fig. 1A. Since the expression level of
HPV-11 E6 was significantly higher than the expression
level of HPV-6 E6, we performed this and the following
experiments with HPV-11 E6. HPV-6 and HPV-11 are
among the two most closely related HPV types, the amino
acid sequence of HPV-11 differing from that of HPV-6 E6
in 28 of 150 residues. Most of these exchanges are conser-
vative, and HPV-6 and HPV-11 are very close relatives with
indistinguishable biological and pathological properties
(Chan et al., 1995; Myers, 1994) (for an exception see
Degenhardt and Silverstein, 2001a). Equal amounts of the
HPV-11 and HPV-16 E6 GST fusion proteins were immo-
bilized on GSH beads, followed by the addition of [35S]me-
thionine-labeled in vitro translated (IVT) TRIP-Br1 and
IVT C-terminal hMCM7 (residues 563–719). Fig. 1B shows
that the IVT TRIP-Br1 bound with almost the same affinity
to both E6 proteins, while we detected no binding of TRIP-
Br1 to GST alone.
As a reference to the binding efficiency of TRIP-Br1
protein to HPV-11 and 16 E6 proteins, we chose a previ-
ously identified cellular interacting partner, namely the hu-
man minichromosome maintenance 7 (hMCM7) protein,
which is involved in the control of the cellular replication
process (Kukimoto et al., 1998). The C-terminal region
(residues 563 to 719) of hMCM7 has been demonstrated to
bind HPV-11 and -16 E6 (Zimmermann et al., 2000). The
bottom of Fig. 1B shows that IVT hMCM7 binds with equal
affinity to both E6 proteins, but with only 15% of the
affinity of TRIP-Br1, confirming the validity of the this
interaction.
Binding between TRIP-Br1 and HPV-11 and HPV-16 E6
proteins in vivo
To demonstrate that HPV E6 proteins bind to TRIP-Br1
in vivo, 293T cells were transfected with plasmids express-
ing the FLAG-tagged TRIP-Br1 together with GST-tagged
HPV-11 E6, HPV-16 E6, or GST alone. Twenty-four hours
after transfection, the cells were lysed and TRIP-Br1-E6
complexes were captured on GSH beads. The samples were
run on sodium dodecylsulfate–polyacrylamide gel electro-
choresis (SDS–PAGE), followed by blotting onto a nitro-
cellulose membrane and bound TRIP-Br1 protein visualized
with an anti-FLAG antibody.
Fig. 2A shows that the TRIP-Br1 protein gave equally
strong signals with lysates of cells cotransfected with the
TRIP-Br1 and either HPV-11 or -16 E6 constructs, while it
was undetectable in the lysate cotransfected with TRIP-Br1
and the GST expression constructs. Fig. 2B shows direct
anti-FLAG Western blotting of whole cell lysates, indicat-
ing that approximately similar amounts of TRIP-Br1 pro-
teins were expressed, while the panel on the right shows
roughly equal amounts of GST E6 fusion proteins being
expressed as well. These results confirm that TRIP-Br1 is
able to bind to HPV-11 and -16 E6 proteins in vivo.
An LLG motif of TRIP-Br1 potentially contributes to the
interaction with HPV E6 proteins
The E6 proteins of papillomaviruses interact with their
multiple cellular targets by various mechanisms, most of
which are not understood in much detail, in particular, since
the three-dimensional structures of E6 proteins are not yet
known. However, about half of all known cellular E6 targets
possess an LLG motif (Kuhne and Banks, 1998; Mantovani
and Banks, 2001), which contributes to the interaction with
E6 (Chen et al., 1998). By inspecting the 236 amino acid
sequence of TRIP-Br1, we observed such an LLG motif at
positions 157–159. To study whether this LLG motif plays
a role in the binding of TRIP-Br1, we altered the coding
sequence in two ways, namely by replacing the LLG se-
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quence with an AAA motif, and by deleting these three
amino acids altogether. A GST pull-down experiment in
Fig. 3 shows that the binding affinity of these two mutations
between HPV-11 E6 and HPV-16 E6 is reduced. By com-
paring with the wild-type (wt) TRIP-Br1 protein, the reduc-
tion in binding efficiency was 30 to 35%, as determined
from using the Bio-Rad densitometer software via integra-
tion of the bands. We conclude that the LLG motif contrib-
utes to but is not alone responsible for the interaction with
E6.
Stability of TRIP-Br1 in the presence of HPV E6 proteins
The E6 proteins of papillomaviruses can catalyze the
modulation of cellular target proteins by inducing proteo-
lytic degradation via the ubiquitination pathway. To exam-
ine this potential mechanism, we mixed in vitro translated
[35S]methionine-labeled p53 and TRIP-Br1 proteins with
[35S]methionine-labeled HPV-11 and HPV-16 E6 proteins.
Fig. 4A shows that neither HPV-11 nor HPV-16 E6 proteins
affect the stability of TRIP-Br1 over 5 h, while Fig. 4B
indicates strong degradation of p53 under the influence of
HPV-16 E6, and a slight degradation by HPV-11 E6, as
expected from published research (Scheffner et al., 1990,
1993). We conclude that the TRIP-Br1 protein is not a target
for E6-induced degradation.
HPV-11 and HPV-16 E6 proteins further increase the
transcription stimulation of E2F1/DP1 by TRIP-Br1
TRIP-Br1 is a transcriptional coactivator of E2F1/DP1.
This function has been studied in the context of the myb
promoter, which is solely dependent on this transcription
factor, as shown by some of us (Hsu et al., 2001). Since both
factors are present in many commonly used cell lines, it is
difficult to study effects of externally added TRIP-Br1 on
E2F1/DP1. We have determined, however, that such effects
can be monitored with a novel construct, pGL3-
TATA6xE2F, which has six E2F1/DP1 binding sites up-
stream of a TATA box and the luciferase reporter gene (Hsu
et al., 2001).
To examine whether HPV E6 proteins could influence
TRIP-Br1 transactivation ability, we cotransfected COS-7
cells with pCMV-E2F1, pCMV-DP1, the firefly luciferase
expression vector pGL3-TATA6xE2F, pXJ40-TRIP-Br1
(FLAG tagged), and the control Renilla luciferase reporter
plasmid, pRL-CMV, in the presence or absence of expres-
sion vectors expressing FLAG-tagged HPV-11 and -16 E6
proteins.
Columns 1 and 2 of Fig. 5 show the background level of
expression of the reporter construct (pGL3-TATA6xE2F)
and the approximately threefold stimulation after transfec-
tion of the TRIP-Br1 expression vector. Transfection of the
Fig. 1. Binding of TRIP-Br1 and HPV E6 proteins in vitro. (A) The GST, HPV-11, and HPV-16 GST fusion proteins are expressed at similar concentrations
in E. coli BL21, as seen from the Coomassie blue stained SDS gel. (B) [35S]methionine-labeled in vitro translated (IVT) TRIP-Br1 binds to GST-linked and
GSH column bound HPV-11 and HPV-16 E6 proteins with similar affinity. In comparison to the binding efficiency of TRIP-Br1, the lower panel indicates
that the IVT C-terminal hMCM7 binds to both HPV-11 and HPV-16 E6 proteins with equal affinity as well but at a lower binding efficiency of about 15%
as determined by the Bio-Rad densitometer software. The numbers on the right side of the figures refer to size markers not included in this figure. Total input
of in vitro translated TRIP-Br1 and hMCM7 proteins in the experiment was at 20%.
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HPV-11 and HPV-16 E6 constructs alone stimulates lucif-
erase activity similarly due to endogenous E2F1/DP1 and
TRIP-Br1 present in the cell line (columns 3 and 4). Co-
transfection of TRIP-Br1 and HPV-11 E6 or -16 E6 leads to
an approximately 4-fold stimulation of the promoter activity
over the level obtained with only one of these proteins and
about 12-fold over the basal level, respectively (columns 5
and 6). The transfection of E2F1/DP1 alone stimulates the
luciferase expression level again due to endogenous TRIP-
Br1 (column 7), which can be further stimulated by cotrans-
fection with TRIP-Br1 (column 8). Cotransfection of E2F1/
DP1 and either one of the two HPV E6 vectors increases
luciferase expression about threefold over the level reached
with E2F1/DP1 alone (columns 9 and 10). This expression
level again doubles if additional TRIP-Br1 is cotransfected
(columns 11 and 12). The combined effects of E2F1/DP1,
TRIP-Br1, and either of the E6 expression vectors lead to
more than 30-fold stimulation over the luciferase levels
achieved in the absence of any of these expression vectors.
We conclude that HPV-11 and -16 E6 proteins have coac-
tivator function in E2F1/DP1/TRIP-Br1-mediated transcrip-
tion. A similar result was observed when we used 293T cells
in place of COS-7 cells (data not shown).
Discussion
High- and low-risk HPVs are infectious agents that alter
the physiology of the infected cell in a way favorable to
viral replication. To permit viral replication in the mitoti-
cally incompetent suprabasal epithelial cells, HPVs have to
exercise strategies that permit passage through cell-cycle
check points. Several of these properties are known and
discussed below, and this article describes yet another one
of these strategies, a function of the E6 oncoprotein to
up-regulate the activity of E2F1/DP1, which is indepen-
dently stimulated by the second HPV oncoprotein, E7,
through its interference with the repressor function of the
RB protein.
The heterodimeric transcription factor E2F1/DP1 plays a
Fig. 2. Binding of TRIP-Br1 to HPV-E6 proteins in vivo. (A) 293T cells were transfected with 2.5 g each of pXJ-derived vectors expressing FLAG-tagged
TRIP-Br1 together with GST, GST-tagged HPV-11, or 16 E6 as indicated. Twenty-four hours after transfection, cells were lysed and incubated with GSH
beads, followed by Western blotting with anti-FLAG antibody. TRIP-Br1  GST, TRIP-Br1  GST 11E6, or TRIP-Br1  GST 16E6 refer to constructs
transfected together. The blot shows TRIP-Br1 binding to both HPV-11 and 16 E6 fusion proteins with similar affinity, while there was no binding detected
with the GST protein alone. (B) Direct anti-FLAG and anti-GST Western blotting of whole cell lysate indicates equal expression of FLAG-tagged TRIP-Br1
and GST-tagged HPV-11 or HPV-16 E6, respectively, in the transfected cells.
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crucial role at the G1/S check point of the cell cycle, as it
controls the expression of a number of rate-limiting factors
for cellular DNA synthesis. The activation function of
E2F1, can be repressed by formation of a complex with RB
and several related proteins, which mask the transcription
activation domain of E2F1 and form additional complexes
with transcriptional repressors such as histone acetyl trans-
ferases (HDACs). The formation of the E2F1–RB complex
is inhibited by cyclin-dependent kinases, which on their part
are stimulated by cyclins and repressed by inhibitors such as
p16INK4a. This well-established model may require further
modifications, as it recently became clear that several re-
lated factors within the E2F family have in part antagonistic
functions (for references and reviews see Dyson, 1998;
Khleif et al., 1996; Trimarchi and Lees, 2002). The HPV E7
proteins and unrelated proteins of polyoma- and adenovi-
ruses alter this fine-tuned mechanism by abrogating the
interaction between RB and E2F1 (Munger et al., 2001).
While this mechanism alone is sufficient to induce certain
carcinogenic processes in transgenic mice (Song et al.,
2000), the most frequent consequence of this disturbance of
the cell cycle is the induction of apoptosis under the influ-
ence of p53 (Mantovani and Banks, 2001). Consequently,
degradation of p53 by the E6 oncoprotein does not only
serve to deregulate a second cell-cycle check point and
thereby favor the carcinogenic progression, but is also a
necessity to avoid that the E7-affected cell proceeds into
apoptosis.
TRIP-Br1 binds the DP1 subunit of E2F1/DP1 and func-
tions as transcriptional cofactor and integrator of regulatory
signals by recruiting PHD-zinc finger and bromodomain-
containing factors such as KRIP-1 and p300/CBP (for de-
tails see Fig. 9 in Hsu et al., 2001). In other words, TRIP-
Br1 modulates transcription of genes relevant for G1/S
transition in the same direction as the oncoprotein E7 does.
Here we report that the E6 oncoprotein further stimulates
this TRIP-Br1 function and that the E2F1/DP1 factor is
dually influenced by both oncoproteins. Fig. 6 schematically
visualizes these mechanisms. This finding is of particular
interest, as this mechanism is also employed by low-risk
HPV types, which have been reported to use only a subset
of the molecular transformation mechanisms used by the E6
and E7 proteins of high-risk HPVs (Mantovani and Banks,
Fig. 3. An LLG motif potentially contributes to the binding between E6 and
TRIP-Br1. (A) Identical input of 20% in each of the three lanes; the central
panels (B,C) show the differential binding affinity of the wild-type (wt)
TRIP-Br1 protein, LLG to AAA substitution, and LLG deleted mutant
TRIP-Br1 proteins to HPV-11 E6 and -16 E6. Both mutant IVT TRIP-Br1
proteins show a 30 to 35% reduction in binding affinity. (D) The lack of
binding of all three types of IVT TRIP-Br1 to GST alone. IVT-translated
TRIP-Br1 frequently appeared in our experiments with a weaker faster
migrating band due to unknown translational/posttranslational effects.
Fig. 4. E6 does not lead to degradation of TRIP-Br1. Approximately equal
amounts of [35S]methionine-labeled TRIP-Br1 or p53 were mixed with
[35S]methionine-labeled HPV-11 or -16 E6 proteins and analyzed for
degradation of up to 5 h. As a negative control, water was added to both
[35S]methionine-labeled TRIP-Br1 and p53 in a total volume equal to that
of the test reactions and incubated for 5 h as well. (A) shows that neither
HPV-11 nor HPV-16 E6 affect the stability of TRIP-Br1 over 5 h, while
(B) shows strong degradation of p53 under the influence of HPV-16 E6,
and a slight effect by HPV-11 E6. As a control, (C) shows the concentra-
tions of the E6 proteins were largely unaffected over the time course of the
experiment.
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2001; Munger et al., 2001). It is particularly notable that we
have detected a natural transcription activation scenario
induced by papillomavirus E6 proteins. Transcription acti-
vation functions of the E6 proteins of the bovine papillo-
mavirus-1 and of HPV-16 have been observed and exten-
sively studied in the context of artificial vector systems, but
could not yet address the question of a natural transcription
activation context stimulated by E6 (Chan et al., 1995;
Desaintes et al., 1992; Lamberti et al., 1990).
Materials and methods
Yeast two-hybrid techniques
Yeast two-hybrid screens were done with the Clontech
Matchmaker Gal4 System (Clontech Laboratories, Palo
Alto, CA) by cloning the E6 genes of HPV-6, HPV-11, and
HPV-16 as polymerase chain reaction (PCR) generated
fragments into the EcoRI and BamHI sites of the bait plas-
mid, pAS2-1, which were expressed in Saccharomyces cer-
evisiae Y190 with N-terminal Gal4 DNA-binding domains.
The pAS2-1 HPV-6 and 16 E6 vectors were tested against
a human foreskin cDNA library with 5.0  106 primary
recombinants with an average insert size of 1 kb from
Clontech Laboratories. The cDNA was cloned into the
EcoRI site of pGAD10 with an N-terminal Gal4 activation
domain.
We established the pAS2-1 E6 constructs in Y190 cells
by selection of a Trp marker and confirmation of stable
maintenance of the E6 inserts by PCR and transformed
cultures of individual clones with the pGAD10 library
DNA. Y190 is histidine auxotroph and does not express the
E. coli LacZ. The His and LacZ markers can be ex-
pressed from chromosomally integrated genes, depending
on the establishment of Gal4 transcription factors dimerized
by HPV E6 domains and putative E6 interacting cellular
proteins expressed from the cDNA library. The Y190 cells
were by an order of magnitude more transformation com-
petent than CG1945 and used for this project, although it
was necessary to inhibit the leaky His3 marker with 25 mM
3-AT (3-amino-1,2,4-triazole). Transformants were selected
for Leu and Trp prototrophy (to select for the two vec-
tors) and for His prototrophy, to identify vectors with E6
interacting inserts. His colonies were lifted on filter papers
and examined for LacZ expression by X-Gal (5-bromo-4-
chloro-3-indoyl-b-D-galactopyranoside) assays.
In vitro binding assay
HPV-11 and HPV-16 E6 proteins were expressed in E.
coli BL21 in the form of glutathione-S-transferase (GST)
fusions after cloning the E6 genes into modified
pGEX2TKP vectors (a derivative of the Pharmacia vector
pGEX2TK with a new polylinker) as described (Zimmer-
Fig. 5. Cooperative stimulation of E2F1/DP1 responsive luciferase expression by TRIP-Br1 and HPV 11/16 E6 proteins. COS-7 cells were transiently
transfected with the indicated expression constructs, 200 ng of the pGL3-TATA6XE2F luciferase reporter plasmid, 2 ng of E2F/DP1 each, 350 ng of
TRIP-Br1, 400 ng HPV-11 E6 or -16 E6. As an internal standard 10 ng of the Renilla luciferase plasmid pRL-CMV was added. Values represent the average
of three independent experiments. Fold activation refers to luciferase activity normalized to Renilla luciferase activity and is expressed relative to the activity
observed with the expression of the experimental reporter (pGL-3TATA6XE2F) and the control reporter (pRL-CMV) alone.
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mann et al., 1999). The proteins were extracted with lysis
buffer [50 mM Tris–HCl (pH 8.0), 5 mM dithiothreitol
(DTT), 150 mM KCl, 0.1% Triton X-100, and 10% glyc-
erol] and, after sonication and centrifugation, stored at
80°C. The lysates were incubated under rotation with
glutathione-Sepharose (GSH) beads (Pharmacia) for about
3 h at 4°C in 1 NENT buffer (100 mM NaCl, 1 mM
EDTA, 0.5% Nonidet P-40, Tris–HCl (pH 8.0)]. After cen-
trifugation and two washes with 1 ml of 1 NENT, the
beads were loaded into a pipette tip containing a glass bead
(BDH; catalog no. 332134Y) to create a 40 l GST mi-
croaffinity column.
In vitro transcription and translation of [35S]methionine-
labeled (Perkin-Elmer) TRIP-Br1, which was subcloned
from the cDNA obtained in the pGAD10 vector in the form
of a BamHI and HindIII restriction fragment into the pXJ40-
FLAG vector (Xiao et al., 1991), was based on TNT T7
rabbit reticulocyte kits (Promega). The C-terminal hMCM7
(residues 563 to 719) construct was subcloned in the form of
BamHI and HindIII restriction fragments into the pXJ40-
FLAG vector (Zimmermann et al., 2000) and underwent the
same procedure of in vitro transcription and translation as
mentioned above. Briefly, 40 l of a 50 l IVT reaction
mixture was diluted with 360 l of binding buffer [50 mM
KCl, 40 mM HEPES (pH 7.5), 1 mM DTT, 0.1% Tween 20,
0.5% milk powder] and passed through the GST microaf-
finity column. After the column was washed twice with 200
l of wash buffer (binding buffer with 150 mM instead of
50 mM KCl), the GSH beads were resuspended with wash
buffer, transferred to a fresh microcentrifuge tube, and pel-
leted by gentle centrifugation. Bound 35S-labeled proteins
were dislodged from the beads with 40 l of an SDS-
containing loading buffer, heated to 95°C for 5 min, and
centrifuged at 14,000 rpm for 30 s; the supernatant was
resolved on a SDS–12% PAGE and visualized by autora-
diography. The resulting bands after autoradiography were
integrated by using the Bio-Rad densitometer software.
In vivo binding assay
The HPV-11 and -16 E6 genes were subcloned in the
form of BamHI and HindIII restriction fragments into the
vector pXJ40-GST (Zimmermann et al., 1999) for expres-
sion as GST-tagged proteins. FLAG-tagged TRIP-Br1 pro-
teins were expressed from the pXJ40-FLAG vector, as de-
scribed above. 293T cells were grown in 10-cm dishes and
transfected with 2.5 g each of pXJ40 encoding the FLAG-
tagged TRIP-Br1 and together with either pXJ40 encoding
the GST-tagged HPV-11, 16 E6 genes, or GST alone, by
using Superfect transfection reagent, in accordance with the
manufacturer’s recommendations (Qiagen, Hilden, Ger-
many). Twenty-four hours after transfection, the cells were
washed in phosphate-buffered saline (PBS) before being
harvested in 0.5 ml lysis buffer [150 mM NaCl, 50 mM
Tris–HCl (pH 7.5), 1 mM EGTA, 0.5% NP-40, 1 mM DTT,
and “Complete EDTA-free” protease inhibitor cocktail
(Roche)]. The extracts were rotated at 4°C for 30 min and
centrifuged at 12,000 rpm for 10 min. The resulting lysates
were incubated with 50 l of GSH beads (washed twice
with lysis buffer first) for 3 h at 4°C with rotation. After
which, the samples were washed twice at 4°C in 0.5 ml lysis
buffer, boiled at 95°C for 5 min in 40 l SDS loading
buffer, resolved by SDS–12% PAGE, blotted onto a nitro-
cellulose membrane, processed with mouse anti-FLAG
monoclonal antibody (Upstate Biotech, US), and detected
with the enhanced chemiluminescence (ECL) detection sys-
tem (Amersham, Piscataway, NJ).
Mutation of the LLG motif of TRIP-Br1 and in vitro
interaction between TRIP-Br1 mutants and E6 proteins
To examine the function of a leucine-leucine-glycine
(LLG) motif in TRIP-Br1, we (i) substituted this motif by a
trimeric alanine repeat (AAA) and (ii) deleted this sequence
Fig. 6. Schematic representation of the effects of the HPV E6 and E7
oncoproteins on the function of the transcription factor E2F1/DP1. In the
absence of coactivators, E2F1/DP1 has an inherent transcription activation
function due to the activation domains of these two subunits (A). This
activation function is suppressed by forming a complex with hypophos-
phorylated RB protein (B). The HPV oncoprotein E7 interferes with bind-
ing of RB and restores the activation function of E2F1/DP1 (C). The
coactivator TRIP-Br1, possibly in cooperation with additional factors such
as CBP/p300, hyperstimulates E2F1/DP1 activity (D). The HPV oncopro-
tein E6 has transcription coactivator function, as it further stimulates this
function of TRIP-Br1 (E).
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completely. We obtained commercially 56 nucleotide prim-
ers encoding centrally the LLG to AAA substitution or
deletion of LLG completely and targeted them to the TRIP-
Br1 gene cloned in the pXJ40 FLAG vector. Products were
generated by PCR with the ExSite Kit (Stratagene) using the
Pfu DNA polymerase and the template DNA removed with
DpnI before transformation into E. coli as described by the
manufacturer. In vitro translation of wild-type TRIP-Br1,
both mutant TRIP-Br1 proteins, and GST pull-down with
GST, GST-tagged HPV-11, and 16 E6 proteins were per-
formed as described earlier. After washing and elution of
bound proteins, the samples were boiled at 95°C for 5 min
with 40 l SDS loading buffer and centrifuged at 14,000
rpm for 30 s and the supernatant was loaded on a SDS–12%
PAGE gel. The resulting bands after autoradiography were
integrated by using the Bio-Rad densitometer software.
Stability of TRIP-Br1 in the presence of E6 proteins
TRIP-Br1, p53 and HPV-11 and 16 E6 proteins were
translated in vitro as described above. To achieve equimolar
concentrations, 5 l of [35S]methionine-labeled IVT TRIP-
Br1 or p53 was mixed with 25 l of [35S]methionine-
labeled IVT HPV-11 or -16 E6 protein and incubated at
30°C for up to 5 h. Five microliters of the reaction mixture
was extracted at the start, at 3 h and at the end of 5 h of the
reaction, stopped by adding 40 l of SDS loading buffer,
and boiled at 95°C for 5 minutes. Twenty microliters of the
mixture was then resolved by SDS–12% PAGE and ana-
lyzed by autoradiography.
Transient transfection studies and luciferase assays
The transcription activation function of TRP-Br1 and its
stimulation by HPV E6 proteins was measured with the
Dual-Luciferase Reporter Assay system (Promega) by
transfecting COS-7 cells with various amounts of the indi-
cated expression plasmids, i.e., pCMV-E2F1, pCMV-DP1,
the firefly luciferase expression vector pGL3-TATA6xE2F,
pXJ40-TRIP-Br1 (FLAG Tagged), and the control Renilla
luciferase reporter plasmid, pRL-CMV, in the presence or
absence of FLAG-tagged HPV-11 and -16 E6 expression
vectors. pGL3-TATA6xE2F had been constructed by two of
us (Yang, C.M., and Hsu, S.I., unpublished data). It contains
six repeated E2F/DP1 binding sites. 1 104 cells/well were
seeded into 24-well plates 24 h before transfection, in
DMEM medium supplemented with 10% fetal bovine se-
rum and antibiotics, and transfected with the Polyfect re-
agent (Qiagen) in accordance with the manufacturer’s in-
structions. The total amount of DNA transfected was kept
constant at 1 g per well. The cells were harvested after
24 h by removal of the medium, washing with PBS, and
adding 100 l of 1 passive lysis buffer (Promega). The
plates were rocked at 200 rpm for 30 min at room temper-
ature, followed by a cycle of freeze/thaw lysis after 1 h at
80°C. The activity of the firefly luciferase was measured
using a Turner TD-20/20 luminometer as instructed by the
manufacturer (Promega), i.e., 20 l of cell lysate was mixed
with 100 l of luciferase assay substrate (Promega), and the
luciferase activity was recorded as the mean of three inde-
pendent transfections. The luciferase activity was standard-
ized against the activity of the control Renilla luciferase
reporter, pRL-CMV, which serves as the baseline response.
References
Chan, S.Y., Delius, H., Halpern, A.L., Bernard, H.U., 1995. Analysis of
genomic sequences of 95 papillomavirus types: uniting typing, phylog-
eny, and taxonomy. J. Virol. 69 (5), 3074–3083.
Chen, J.J., Hong, Y., Rustamzadeh, E., Baleja, J.D., Androphy, E.J., 1998.
Identification of an alpha helical motif sufficient for association with
papillomavirus E6. J. Biol. Chem. 273 (22), 13537–13544.
Das, K., Bohl, J., Vande Pol, S.B., 2000. Identification of a second trans-
forming function in bovine papillomavirus type 1 E6 and the role of E6
interactions with paxillin, E6BP, and E6AP. J. Virol. 74 (2), 812–816.
Degenhardt, Y.Y., Silverstein, S., 2001a. Interaction of zyxin, a focal
adhesion protein, with the e6 protein from human papillomavirus type
6 results in its nuclear translocation. J. Virol. 75 (23), 11791–11802.
Degenhardt, Y.Y., Silverstein, S.J., 2001b. Gps2, a protein partner for
human papillomavirus E6 proteins. J. Virol. 75 (1), 151–160.
Desaintes, C., Hallez, S., Van Alphen, P., Burny, A., 1992. Transcriptional
activation of several heterologous promoters by the E6 protein of
human papillomavirus type 16. J. Virol. 66 (1), 325–333.
Dyson, N., 1998. The regulation of E2F by pRB-family proteins. Genes
Dev. 12 (15), 2245–2262.
Gewin, L., Galloway, D.A., 2001. E box-dependent activation of telomer-
ase by human papillomavirus type 16 E6 does not require induction of
c-myc. J. Virol. 75 (15), 7198–7201.
Howley, P.M., Ed., 1996. Papillomaviridae: the viruses and their replica-
tion, third ed, Fields, B.N., Knipe, D.M., Howley, P.M., (Eds.), Fields
Virology, Lippincott-Raven, Philadelphia.
Hsu, S.I., Yang, C.M., Sim, K.G., Hentschel, D.M., O’Leary, E., Bonven-
tre, J.V., 2001. TRIP-Br: a novel family of PHD zinc finger- and
bromodomain-interacting proteins that regulate the transcriptional ac-
tivity of E2F-1/DP-1. EMBO J. 20 (9), 2273–2285.
Huibregtse, J.M., Scheffner, M., Howley, P.M., 1993. Localization of the
E6-AP regions that direct human papillomavirus E6 binding, associa-
tion with p53, and ubiquitination of associated proteins. Mol. Cell Biol.
13 (8), 4918–4927.
IARC, 1995. Human Papillomaviruses. IARC Monographs on the Evalu-
ation of Carcinogenic Risks to Humans.
Khleif, S.N., DeGregori, J., Yee, C.L., Otterson, G.A., Kaye, F.J., Nevins,
J.R., Howley, P.M., 1996. Inhibition of cyclin D-CDK4/CDK6 activity
is associated with an E2F-mediated induction of cyclin kinase inhibitor
activity. Proc. Natl. Acad. Sci. USA 93 (9), 4350–4354.
Kiyono, T., Hiraiwa, A., Fujita, M., Hayashi, Y., Akiyama, T., Ishibashi,
M., 1997. Binding of high-risk human papillomavirus E6 oncoproteins
to the human homologue of the Drosophila discs large tumor suppres-
sor protein. Proc. Natl. Acad. Sci. USA 94 (21), 11612–11616.
Kuhne, C., Banks, L., 1998. E3-ubiquitin ligase/E6-AP links multicopy
maintenance protein 7 to the ubiquitination pathway by a novel motif,
the L2G box. J. Biol. Chem. 273 (51), 34302–34309.
Kukimoto, I., Aihara, S., Yoshiike, K., Kanda, T., 1998. Human papillo-
mavirus oncoprotein E6 binds to the C-terminal region of human
minichromosome maintenance 7 protein. Biochem. Biophys. Res.
Commun. 249, 258–262.
163S. Gupta et al. / Virology 317 (2003) 155–164
Lamberti, C., Morrissey, L.C., Grossman, S.R., Androphy, E.J., 1990.
Transcriptional activation by the papillomavirus E6 zinc finger onco-
protein. EMBO J. 9 (6), 1907–1913.
Lee, S.S., Weiss, R.S., Javier, R.T., 1997. Binding of human virus onco-
proteins to hDlg/SAP97, a mammalian homolog of the Drosophila
discs large tumor suppressor protein. Proc. Natl. Acad. Sci. USA 94
(13), 6670–6675.
Mantovani, F., Banks, L., 2001. The human papillomavirus E6 protein and
its contribution to malignant progression. Oncogene 20 (54), 7874–
7887.
Munger, K., Basile, J.R., Duensing, S., Eichten, A., Gonzalez, S.L., Grace,
M., Zacny, V.L., 2001. Biological activities and molecular targets of
the human papillomavirus E7 oncoprotein. Oncogene 20 (54), 7888–
7898.
Myers, G., Bernard, H.U., Delius, H., Favre, M., Icenogle, J., van Ranst,
M., Wheeler, C., 1994. Human Papillomaviruses, II-E6-2-6. Los
Alamos National Laboratory, Los Alamos, NM.
Ned, R., Allen, S., Vande Pol, S., 1997. Transformation by bovine papil-
lomavirus type 1 E6 is independent of transcriptional activation by E6.
J. Virol. 71 (6), 4866–4870.
Patel, D., Huang, S.M., Baglia, L.A., McCance, D.J., 1999. The E6 protein
of human papillomavirus type 16 binds to and inhibits co-activation by
CBP and p300. EMBO J. 18 (18), 5061–5072.
Rapp, L., Chen, J.J., 1998. The papillomavirus E6 proteins. Biochim.
Biophys. Acta. 1378 (1), F1–19.
Ronco, L.V., Karpova, A.Y., Vidal, M., Howley, P.M., 1998. Human
papillomavirus 16 E6 oncoprotein binds to interferon regulatory fac-
tor-3 and inhibits its transcriptional activity. Genes Dev. 12 (13),
2061–2072.
Scheffner, M., Huibregtse, J.M., Vierstra, R.D., Howley, P.M., 1993. The
HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase
in the ubiquitination of p53. Cell 75 (3), 495–505.
Scheffner, M., Werness, B.A., Huibregtse, J.M., Levine, A.J., Howley,
P.M., 1990. The E6 oncoprotein encoded by human papillomavirus
types 16 and 18 promotes the degradation of p53. Cell 63 (6), 1129–
1136.
Song, S., Liem, A., Miller, J.A., Lambert, P.F., 2000. Human papilloma-
virus types 16 E6 and E7 contribute differently to carcinogenesis.
Virology 267 (2), 141–150.
Sugimoto, M., Nakamura, T., Ohtani, N., Hampson, L., Hampson, I.N.,
Shimamoto, A., Furuichi, Y., Okumura, K., Niwa, S., Taya, Y., Hara,
E., 1999. Regulation of CDK4 activity by a novel CDK4-binding
protein, p34(SEI-1). Genes Dev. 13 (22), 3027–3033.
Trimarchi, J.M., Lees, J.A., 2002. Sibling rivalry in the E2F family. Nat.
Rev. Mol. Cell Biol. 3 (1), 11–20.
Ullman, C.G., Haris, P.I., Galloway, D.A., Emery, V.C., Perkins, S.J.,
1996. Predicted alpha-helix/beta-sheet secondary structures for the
zinc-binding motifs of human papillomavirus E7 and E6 proteins by
consensus prediction averaging and spectroscopic studies of E7. Bio-
chem. J. 319 (Pt. 1), 229–239.
Vande Pol, S.B., Brown, M.C., Turner, C.E., 1998. Association of bovine
papillomavirus type 1 E6 oncoprotein with the focal adhesion protein
paxillin through a conserved protein interaction motif. Oncogene 16
(1), 43–52.
Werness, B.A., Levine, A.J., Howley, P.M., 1990. Association of human
papillomavirus types 16 and 18 E6 proteins with p53. Science 248
(4951), 76–79.
Xiao, J.H., Davidson, I., Matthes, H., Garnier, J.M., Chambon, P., 1991.
Cloning, expression, and transcriptional properties of the human en-
hancer factor TEF-1. Cell 65 (4), 551–568.
Zimmermann, H., Degenkolbe, R., Bernard, H.U., O’Connor, M.J., 1999.
The human papillomavirus type 16 E6 oncoprotein can down-regulate
p53 activity by targeting the transcriptional coactivator CBP/p300.
J. Virol. 73 (8), 6209–6219.
Zimmermann, H., Koh, C.H., Degenkolbe, R., O’Connor, M.J., Muller, A.,
Steger, G., Chen, J.J., Lui, Y., Androphy, E., Bernard, H.U., 2000.
Interaction with CBP/p300 enables the bovine papillomavirus type 1
E6 oncoprotein to downregulate CBP/p300-mediated transactivation by
p53. J. Gen. Virol. 81 (Pt. 11), 2617–2623.
zur Hausen, H., 1996. Papillomavirus infections—a major cause of human
cancers. Biochim. Biophys. Acta 1288 (2), F55–F78.
164 S. Gupta et al. / Virology 317 (2003) 155–164
